November 18, 2026
Health news, explained with evidence
LIVE

Study Highlights Circulating Tumor DNA as a Strong Prognostic Marker in Colorectal Cancer Recurrence

🧠 AI Analysis 2 min read 👁 0

A retrospective study involving 468 patients evaluated circulating tumor DNA to monitor colorectal cancer recurrence after surgery, revealing significant links to disease-free survival.

🧠AI Analysis

Key points

  • Retrospective study evaluated 468 colorectal cancer patients using a molecular residual disease assay.
  • Detection of ctDNA strongly correlated with shorter disease-free survival and anticipated clinical recurrence by a median of 97 days.
  • Adjuvant chemotherapy was linked to improved disease-free survival in ctDNA-positive patients but showed no benefit in ctDNA-negative individuals.

Researchers in the retrospective β-CORRECT study have evaluated the association between circulating tumor DNA (ctDNA), detected via a tumor-informed molecular residual disease assay, and cancer recurrence in 468 patients with Stage II, III, or resectable Stage IV colorectal cancer. Among 417 patients followed for a median of 1.9 years, the detection of ctDNA showed a strong link to shorter disease-free survival across surveillance, post-surgery, and post-definitive therapy phases, independent of standard clinicopathological factors. Furthermore, every ten-fold elevation in ctDNA levels roughly doubled the risk of recurrence, with a median lead time of 97 days between ctDNA detection and clinical relapse.

The findings also highlighted potential treatment interactions, observing that adjuvant chemotherapy correlated with improved disease-free survival among ctDNA-positive individuals, while no such benefit appeared in ctDNA-negative patients. Additionally, the researchers identified significant associations between ctDNA status and specific genomic alterations, such as RAS, BRAF, WNT, and MAPK pathways, alongside distinct RNA expression patterns related to epithelial-mesenchymal transition.

What to know: While these results suggest ctDNA could serve as a powerful independent prognostic marker to help guide post-surgical treatment choices in resected colorectal cancer, the retrospective design and observational nature mean further prospective trials are necessary to confirm clinical utility. Patients should always consult their oncologist regarding personal care decisions.

Source Nature Health Sciences — nature.com/articles/s41598-026-79295-3 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.